TUBB4A relieves high glucose-induced cardiomyocyte hypertrophy and apoptosis through the regulation of ubiquitination and activation of the NOTCH signaling pathway.
IF 2 4区 生物学Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Jiarui Zhang, Wenwei Bai, Xiaoyong Liu, Jingjing Huang, Zhenxia Feng, Hu Li
{"title":"TUBB4A relieves high glucose-induced cardiomyocyte hypertrophy and apoptosis through the regulation of ubiquitination and activation of the NOTCH signaling pathway.","authors":"Jiarui Zhang, Wenwei Bai, Xiaoyong Liu, Jingjing Huang, Zhenxia Feng, Hu Li","doi":"10.1007/s10616-025-00763-1","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic cardiomyopathy (DCM), a cardiac condition resulting from diabetes, is linked to significant morbidity and mortality rates. TUBB4A, a variant of tubulin, is highly expressed in heart-related illnesses, yet its function in DCM remains unclear. In this study, 60 mg/kg streptozotocin (STZ) was intraperitoneally injected into mice to induce a diabetic model, and 30 mM glucose was added to H9C2 cell medium for 48 h to induce a high glucose (HG) cell model. In this study, TUBB4A expression was decreased in STZ- or HG-induced animal or cellular DCM models. The overexpression of TUBB4A diminished the effects of STZ or HG, enhanced the growth of myocardial cells, and prevented their hypertrophy and apoptosis. Moreover, it inhibited the expression of ROS, Bax and C-Caspase-3; promoted the expression of Bcl-2 and also alleviated DCM in vivo. Mechanistically, TUBB4A interacts with MYH9 and promotes NOTCH1 expression through MYH9-mediated deubiquitination, thereby inhibiting HG-induced cardiomyocyte hypertrophy and apoptosis and alleviating the development of DCM. Our study suggests that increasing TUBB4A expression may be a potential strategy for the treatment of DCM.</p>","PeriodicalId":10890,"journal":{"name":"Cytotechnology","volume":"77 3","pages":"100"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078915/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytotechnology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s10616-025-00763-1","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetic cardiomyopathy (DCM), a cardiac condition resulting from diabetes, is linked to significant morbidity and mortality rates. TUBB4A, a variant of tubulin, is highly expressed in heart-related illnesses, yet its function in DCM remains unclear. In this study, 60 mg/kg streptozotocin (STZ) was intraperitoneally injected into mice to induce a diabetic model, and 30 mM glucose was added to H9C2 cell medium for 48 h to induce a high glucose (HG) cell model. In this study, TUBB4A expression was decreased in STZ- or HG-induced animal or cellular DCM models. The overexpression of TUBB4A diminished the effects of STZ or HG, enhanced the growth of myocardial cells, and prevented their hypertrophy and apoptosis. Moreover, it inhibited the expression of ROS, Bax and C-Caspase-3; promoted the expression of Bcl-2 and also alleviated DCM in vivo. Mechanistically, TUBB4A interacts with MYH9 and promotes NOTCH1 expression through MYH9-mediated deubiquitination, thereby inhibiting HG-induced cardiomyocyte hypertrophy and apoptosis and alleviating the development of DCM. Our study suggests that increasing TUBB4A expression may be a potential strategy for the treatment of DCM.
期刊介绍:
The scope of the Journal includes:
1. The derivation, genetic modification and characterization of cell lines, genetic and phenotypic regulation, control of cellular metabolism, cell physiology and biochemistry related to cell function, performance and expression of cell products.
2. Cell culture techniques, substrates, environmental requirements and optimization, cloning, hybridization and molecular biology, including genomic and proteomic tools.
3. Cell culture systems, processes, reactors, scale-up, and industrial production. Descriptions of the design or construction of equipment, media or quality control procedures, that are ancillary to cellular research.
4. The application of animal/human cells in research in the field of stem cell research including maintenance of stemness, differentiation, genetics, and senescence, cancer research, research in immunology, as well as applications in tissue engineering and gene therapy.
5. The use of cell cultures as a substrate for bioassays, biomedical applications and in particular as a replacement for animal models.